Date: 12/12/2022
Category:
Presentation: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Recent updates
-
August 2023 Update
. Read more
- Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001. Read more
- Ichnos Sciences Welcomes Lida Pacaud, M.D., as New Chief Medical Officer. Read more
-
May 2023 Update . Read more
- Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442. Read more
View Career Opportunities
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
